Ocugen, Inc. (OCGN)
NASDAQ: OCGN · Real-Time Price · USD
1.030
0.00 (0.00%)
At close: Aug 13, 2025, 4:00 PM
1.020
-0.010 (-0.96%)
Pre-market: Aug 14, 2025, 9:09 AM EDT
Ocugen Employees
Ocugen had 95 employees as of December 31, 2024. The number of employees increased by 30 or 46.15% compared to the previous year.
Employees
95
Change (1Y)
30
Growth (1Y)
46.15%
Revenue / Employee
$50,042
Profits / Employee
-$599,853
Market Cap
321.67M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
OCGN News
- 1 day ago - Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease - GlobeNewsWire
- 1 day ago - Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants - GlobeNewsWire
- 5 days ago - Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants - GlobeNewsWire
- 12 days ago - Ocugen, Inc. (OCGN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Ocugen Provides Business Update with Second Quarter 2025 Financial Results - GlobeNewsWire
- 24 days ago - Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team - GlobeNewsWire
- 27 days ago - Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease - GlobeNewsWire
- 4 weeks ago - Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results - GlobeNewsWire